Last update :
08/05/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Vincristine sulfate  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Cellecristin Germany
Citomid Chile, Colombia, Mexico, Peru
Crisovin Colombia, Ecuador, Mexico
Cytocristin Malaysia
DBL vincristine sulfate Malaysia, New Zealand
Farmistin Germany
Marqibo United States of America
Nefixol Mexico
Oncocristin Colombia
Oncovin Austria, Colombia, Denmark, Finland, France, Great Britain, Luxembourg, Mexico, Morocco, Saudi Arabia, Sweden, Switzerland, United Arab Emirates
Onkocristin Germany
Sindovin Iran
Sulfato de vincristine Venezuela
Unicristin Peru
Vinblax Mexico
Vincasar Mexico, United States of America
Vincrisin Belgium
Vincristin Austria, Germany, Hungary, Switzerland
Vincristina Argentina, Chile, Colombia, Ecuador, Iceland, Iran, Italy, Peru, Spain, Venezuela
Vincristine France, Greece, Luxembourg, Malaysia, Morocco, Norway, Sweden, Switzerland, Tunisia, Turkey
Vincristine sulfat Turkey
Vincristine sulfate Canada, United States of America
Vincristine sulphate Egypt, Great Britain, Ireland, Malaysia, New Zealand, Poland, United Arab Emirates
Vincristinesulfaat Netherlands
Vincristinum Luxembourg
Vincrisul Spain
Vinlon Lyo Peru
Vinracine Egypt, Malaysia
Vintec Mexico
Stability of mixtures   Injection   Stability of mixtures : Vincristine sulfate     
Container Solvent Concentration Compound Temperature Storage Duration of stability References
Glass Sodium chloride 0,9% 0,005 mg/ml
Injection   Vincristine sulfate   
Injection   Granisetron hydrochloride 0,5 mg/ml
20°C-23°C
4 Hour
Light 57
Level of evidence A+
Polyvinyl chloride Water for Injection 0,2 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 2 mg/ml
37°C
7 Day
Protect from light 1408
Level of evidence A+
Polyvinyl chloride Water for Injection 0,2 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 2 mg/ml
8°C
14 Day
Protect from light 1408
Level of evidence A+
Polyvinyl chloride Sodium chloride 0,9% 0,028 mg/ml
Injection   Vincristine sulfate   
Injection   Ondansetron hydrochloride 0,96 mg/ml
Injection   Doxorubicin hydrochloride 0,8 mg/ml
30°C
5 Day
Not specified 26
Level of evidence D
Polyvinyl chloride Sodium chloride 0,9% 0,036 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 1,67 mg/ml
35°C
4 Day
Protect from light 32
Level of evidence A+
Polyvinyl chloride Sodium chloride 0,9% 0,036 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 1,67 mg/ml
4°C
7 Day
Protect from light 32
Level of evidence A+
Polyolefine Sodium chloride 0,9% 0,005 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,12 mg/ml
Injection   Etoposide phosphate 0,6 mg/ml
2-6°C
5 Day
Protect from light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,010 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,24 mg/ml
Injection   Etoposide phosphate 1,2 mg/ml
2-6°C
5 Day
Protect from light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,016 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,4 mg/ml
Injection   Etoposide phosphate 2 mg/ml
2-6°C
5 Day
With or without light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,002 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,050 mg/ml
Injection   Etoposide 0,250 mg/ml
23°C-25°C
72 Hour
With or without light 1033
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,001 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,025 mg/ml
Injection   Etoposide 0,125 mg/ml
23°C-25°C
96 Hour
With or without light 1033
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,0014 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,035 mg/ml
Injection   Etoposide 0,175 mg/ml
23°C-25°C
96 Hour
With or without light 1033
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,033 & 0,053 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 1,4 mg/ml
25°C
4 Day
Not specified 2094
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,0016 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,040 mg/ml
Injection   Etoposide 0,200 mg/ml
31°C-33°C
72 Hour
With or without light 1033
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,005 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,12 mg/ml
Injection   Etoposide phosphate 0,6 mg/ml
35°C-40°C
5 Day
Protect from light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,010 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,24 mg/ml
Injection   Etoposide phosphate 1,2 mg/ml
35°C-40°C
5 Day
Protect from light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,016 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,4 mg/ml
Injection   Etoposide phosphate 2 mg/ml
35°C-40°C
5 Day
With or without light 1606
Level of evidence A
Polyolefine Sodium chloride 0,9% 0,033 & 0,053 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 1,4 mg/ml
8°C
14 Day
Not specified 2094
Level of evidence A
Polysiloxane Sodium chloride 0,9% 0,033 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 1,4 mg/ml
25°C
14 Day
Protect from light 408
Level of evidence C
Polysiloxane Sodium chloride 0,9% 0,033 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 1,4 mg/ml
37°C
7 Day
Protect from light 408
Level of evidence C
Polysiloxane NaCl 0,45% Glucose 2,5% 0,033 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 1,4 mg/ml
25°C
14 Day
Protect from light 408
Level of evidence C
Polysiloxane NaCl 0,45% Glucose 2,5% 0,033 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 1,4 mg/ml
37°C
7 Day
Protect from light 408
Level of evidence C
Polyisoprene elastomer Sodium chloride 0,9% 0,005 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,12 mg/ml
Injection   Etoposide phosphate 0,6 mg/ml
2-6°C
14 Day
Not specified 4102
Level of evidence A+
Polyisoprene elastomer Sodium chloride 0,9% 0,01 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,24 mg/ml
Injection   Etoposide phosphate 1,2 mg/ml
2-6°C
14 Day
Not specified 4102
Level of evidence A+
Polyisoprene elastomer Sodium chloride 0,9% 0,016 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,4 mg/ml
Injection   Etoposide phosphate 2 mg/ml
2-6°C
14 Day
Not specified 4102
Level of evidence A+
Polyisoprene elastomer Sodium chloride 0,9% 0,005 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,12 mg/ml
Injection   Etoposide phosphate 0,6 mg/ml
35°C
7 Day
Protect from light 4102
Level of evidence A+
Polyisoprene elastomer Sodium chloride 0,9% 0,01 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,24 mg/ml
Injection   Etoposide phosphate 1,2 mg/ml
35°C
7 Day
Protect from light 4102
Level of evidence A+
Polyisoprene elastomer Sodium chloride 0,9% 0,016 mg/ml
Injection   Vincristine sulfate   
Injection   Doxorubicin hydrochloride 0,4 mg/ml
Injection   Etoposide phosphate 2 mg/ml
35°C
7 Day
Protect from light 4102
Level of evidence A+
Not specified NaCl 0,9% or Glucose 5% 0,5 mg/ml
Injection   Vincristine sulfate   
Injection   Topotecan 0,028 mg/ml
20°C-23°C
4 Hour
Light 1026
Level of evidence C
  Mentions Légales